HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Persistent diastolic dysfunction despite successful long-term octreotide treatment in acromegaly.

AbstractINTRODUCTION:
This study was designed to evaluate potential reversibility of left-ventricular (LV) dysfunction in patients with acromegaly following long-term control of disease. It is unknown whether the cardiac changes induced by acromegaly can be reversed completely by long-term strict control of growth hormone excess by octreotide.
PATIENTS AND METHODS:
We compared LV systolic and diastolic function in inactive patients with acromegaly (n = 22), who were divided into patients with long-term control by octreotide (n = 14) and patients with long-term cure by surgery/radiotherapy (n = 8). We also assessed these parameters in patients with active acromegaly (n = 17).
RESULTS:
In patients with active acromegaly, systolic function at rest was decreased by 18% (P < 0.01), LV mass index increased by 40% (P < 0.04) and isovolumetric relaxation time increased by 19% (P < 0.01), compared with patients with inactive acromegaly. These parameters were not different between well-controlled and cured patients. Using tissue Doppler imaging, the ratio between early and late diastolic velocity (E'/A' ratio) was decreased in active, compared with inactive acromegaly (0.75+/-0.07 versus 1.24+/-0.15; P < 0.01). This E'/A' ratio was considerably higher in cured, compared with octreotide-treated, patients (1.75+/-0.41 versus 1.05+/-0.1; P < 0.01).
CONCLUSION:
Diastolic function is persistently and significantly more impaired in acromegalic patients with long-term control by octreotide than in surgically cured patients, which points to biological effects of subtle abnormalities in growth hormone secretion. Criteria for strict biochemical control of acromegaly should thus be reconsidered.
AuthorsS W van Thiel, J J Bax, N R Biermasz, E R Holman, D Poldermans, F Roelfsema, H J Lamb, E E van der Wall, J W A Smit, J A Romijn, A M Pereira
JournalEuropean journal of endocrinology (Eur J Endocrinol) Vol. 153 Issue 2 Pg. 231-8 (Aug 2005) ISSN: 0804-4643 [Print] England
PMID16061829 (Publication Type: Clinical Trial, Comparative Study, Journal Article)
Chemical References
  • Antineoplastic Agents, Hormonal
  • Human Growth Hormone
  • Octreotide
Topics
  • Acromegaly (complications, drug therapy, surgery)
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Agents, Hormonal (administration & dosage)
  • Diastole
  • Echocardiography, Doppler
  • Female
  • Human Growth Hormone (metabolism)
  • Humans
  • Male
  • Middle Aged
  • Octreotide (administration & dosage)
  • Systole
  • Treatment Outcome
  • Ventricular Dysfunction, Left (diagnostic imaging, etiology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: